25 Jan Strategy and Full Year 2021 Trading Update and Interview with David Allmond
Full year revenue and EBITDA in line with expectations
Committed to becoming a leading, global clinical diagnostics company
Paris, France and Camberley, UK – 25 January 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2021, together with a strategy update following Chief Executive Officer David Allmond’s first 100 days with the Company. Reported revenues and EBITDA for the period are both expected to be in line with expectations. The Company intends to announce its 2021 audited full year results in the week commencing 25 April 2022.
https://novacyt.com/wp-content/uploads/2022/01/Novacyt-2021-Trading-Update.pdf